Physician profile

Thomas D Callahan

Family Medicine · St George, UT

NPI 1043328123

$4,526.29

in general payments reported to CMS, 2019-2025

46 companies · $564 in 2025

The $564 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,693.11

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $785.45 2019-2025 Ubrelvy, Linzess, Viberzi
Novo Nordisk INC $409.01 2019-2025 Rybelsus, Ozempic
Novartis Pharmaceuticals Corporation $351.98 2020-2025
Pfizer INC. $286.94 2019-2025
Amgen INC. $263.53 2019-2025 Repatha, Evenity, Krystexxa
Janssen Pharmaceuticals, INC $238.54 2019-2023 Spravato
Boehringer Ingelheim Pharmaceuticals, INC. $187.83 2020-2025 Jardiance, Synjardy
Lilly USA, LLC $187.40 2019-2025 Mounjaro, Jardiance, Emgality
Merck Sharp & Dohme LLC $149.44 2019-2024 Gardasil 9, Vaxelis, Gardasil
Astrazeneca Pharmaceuticals LP $147.27 2019-2020
Boston Scientific Corporation $137.50 2021-2025 General - Pain Management, Watchman Flx
Otsuka America Pharmaceutical, INC. $104.93 2019-2025 Rexulti
Abbott Laboratories $93.05 2019-2023 Freestyle Libre 2
Nestle Healthcare Nutrition INC. $82.54 2022
Upsher-Smith Laboratories LLC $72.19 2020-2021
Show all 46 companies
CompanyGeneral paymentsYearsTop products
Sanofi-Aventis U.S. LLC $68.69 2019-2021
Aimmune Therapeutics, INC. $66.13 2024-2025 Zenpep
Amarin Pharma, INC. $64.82 2019-2021
Lucid Diagnostics INC. $64.53 2023
Nevro Corp. $63.12 2021-2022
Allergan, INC. $61.20 2019-2020
Dexcom, INC. $55.75 2021-2022
Idorsia Pharmaceuticals US INC $51.03 2024-2025 Quviviq, Quviviq
Alfasigma USA, INC. $46.94 2022
Sanofi Pasteur INC. $39.20 2020-2025
Glaxosmithkline, LLC. $37.92 2022-2024 Arexvy
Neuronetics, INC. $36.52 2024 Neurostar Tms Therapy System
Protega Pharmaceutials INC $35.67 2024 Roxybond
Medtronic, INC. $34.11 2024-2025 Venaseal
Organon LLC $28.42 2025 Nexplanon
Lundbeck LLC $28.16 2025 Rexulti
Kyowa Kirin, INC. $23.69 2025
Biohaven Pharmaceutical Holding Company LTD. $21.12 2022
Ibsa Pharma INC. $20.98 2020
Xeris Pharmaceuticals, INC. $20.16 2022
Impel Pharmaceuticals INC. $18.00 2023 Trudhesa
Horizon Therapeutics Plc $17.79 2023 Krystexxa
Biohaven Pharmaceuticals, INC. $15.53 2021
Alkermes, INC. $15.41 2022
Digestive Care, INC. $15.31 2025 Pertzye
Daiichi Sankyo INC. $14.55 2024 Injectafer
Neurocrine Biosciences, INC. $13.21 2023 Ingrezza, Ongentys
Takeda Pharmaceuticals U.S.A., INC. $13.04 2019
Bayer Healthcare Pharmaceuticals INC. $12.77 2022
Eisai INC. $12.47 2020
Nalpropion Pharmaceuticals LLC $12.45 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Thomas D Callahan

$4,526.29

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $564 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/791549/thomas-d-callahan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.